Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0001964738
$86.67
+0.32% · delayed ~15 min
Last price from Oct 21, 2026
$15.04B market value
From Solventum Corp's FY2025 10-K, filed Feb 27, 2026 · read the filing
Solventum makes medical devices and equipment. It took in $8.32B last year, which makes it a mid-sized company. Of every dollar it sells, about 19 cents is left as profit.
The financial picture is mixed, with profitability and growth needing attention and debt weaker.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From Solventum Corp's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating income
$1.04B → $2.18B
Profit
$479.0M → $1.56B
Operating margin
12.6% → 26.2%
Profit margin
5.8% → 18.7%
Measured against FY2024, from the 10-K filed Feb 27, 2026
Improved: +110.5%
$1.04B to $2.18BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +224.8%
$479.0M to $1.56BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
SOLV rose 0.32% on the latest quote. The average Health Care company tracked here moved +1.62%, and the S&P 500 −1.04%. That is 1.3 points below its sector and 1.4 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 22 analysts covering this company, as of . Their views, not this site's.
Of 22 analysts publishing on this company, 6 say strong buy, 7 say buy, 8 say hold and 1 say sell. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 19 cents of every dollar of sales as profit, earning $1.56B last year. Note that after $379.0M of spending on property and equipment, it consumed $10.0M more cash than it generated.
Barely. Sales were roughly flat, up 0.9%.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $1.56B and generated $369.0M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 27, 2026Filing for FY2025 | FY202410-K · Feb 28, 2025Filing for FY2024 | FY202310-K · Feb 27, 2026Filing for FY2023 | FY202210-K · Feb 28, 2025Filing for FY2022 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|
| RevenueWhat is this? | $8.32B | $8.25B | $8.20B | $8.13B | +0.9% |
| Gross profit | $4.45B | $4.59B | $4.69B | $4.70B | −3.1% |
| Gross marginGross profit ÷ revenueWhat is this? | 53.5% | 55.6% | 57.3% | 57.7% | −2.2 pts |
| Selling, general and administrative | $3.08B | $2.78B | $2.30B | $2.23B | +10.7% |
| Operating income | $2.18B | $1.04B | $1.69B | $1.69B | +110.5% |
| Operating marginOperating income ÷ revenueWhat is this? | 26.2% | 12.6% | 20.6% | 20.8% | +13.6 pts |
| Income before tax | $1.71B | $605.0M | $1.67B | $1.69B | +183.1% |
| Net income | $1.56B | $479.0M | $1.35B | $1.34B | +224.8% |
| Net marginNet income ÷ revenueWhat is this? | 18.7% | 5.8% | 16.4% | 16.5% | +12.9 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $8.97 | $2.77 | $7.79 | $7.78 | +223.5% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| SOLVSolventum Corp · this page | 4.7/10 | 7/9 | 0.9% | 18.7% |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 67,261 shares
Holds 211,983 shares after this filing.
Had shares withheld to cover taxes — 26,468 shares at $90.95 ($2.4M)
Holds 185,515 shares after this filing.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q2 FY2026
Operating margin −1.7 pts · Long-term debt -41.5% · Operating income -15.4% — against Q2 FY2025
Read the filingPublished results
Read the filingWrite down why you are following Solventum Corp, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 112 subsidiaries named in its 10-K, incorporated across 45 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from SOLV's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 27, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 4.7 | 7/9 | 10-K, filed Feb 27, 2026 |
| FY2024 | 4.7 | 4/9 | 10-K, filed Feb 28, 2025 |
| FY2023 | 8.7 | 4/5 | 10-K, filed Feb 28, 2025 |
| FY2022 | 10.0 | 2/2 | 10-K, filed Feb 28, 2025 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
7 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
2.30
In the grey zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +13.7 pts
12.6% to 26.2%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +12.9 pts
5.8% to 18.7%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: turned negative
$805.0M to -$10.0MCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: +223.5%
$2.77 to $8.97Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: -35.5%
$7.81B to $5.04BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +15.2%
$762.0M to $878.0MSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: −2.2 pts
55.6% to 53.5%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 5, 2026 — read it.
Improved: -41.5%
$7.82B to $4.57BCritical
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Deteriorated: -15.4%
$214.0M to $181.0MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +3.8 pts
54.4% to 58.2%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: -18.1%
$492.0M to $403.0MSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +9.4%
$1.18B to $1.29BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: −1.7 pts
9.9% to 8.2%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: -1.9%
173.4M to 170.1MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 5, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: +123.5%
$81.0M to $181.0MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +607.7%
$13.0M to $92.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +621.9%
$0.07 to $0.54Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +17.2%
$1.10B to $1.29BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +3.6 pts
54.7% to 58.2%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +4.2 pts
4.0% to 8.2%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +3.5 pts
0.6% to 4.2%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -28.2%
$561.0M to $403.0MSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +10.1%
$2.01B to $2.21BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: -2.0%
173.5M to 170.1MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
4 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.8% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Yes. Clearing its debt would take roughly 11.3 years of cash flow. For every $1 it owes, it owns $1.55 in assets.
The trailing P/E is 10.3x — investors pay $10.3 for each $1 of trailing profit.
This company has not reported enough of the required figures to calculate this score.
| 9.66x |
| 1.83x |
| ALGNALIGN TECHNOLOGY INC | 8.7/10 | 6/8 | 0.9% | 10.2% | 27.04x | 0.54x |
|---|
| Median of peers | 8.7/10 | — | 0.9% | 10.2% | 27.04x | 0.54x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Made a Regulation FD disclosure · Reported another event
Had a director or senior officer leave or join
Read the filingReported another event
Read the filingHad a director or senior officer leave or join
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Operating margin −3.3 pts · Operating income -46.7% · Profit -90.5% — against Q1 FY2025
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingHad a director or senior officer leave or join
Read the filingAnnual report for FY2025
Operating margin +13.7 pts · Operating income +110.5% · Profit +224.8% — against FY2024
Read the filingPublished results
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Operating margin +67.4 pts · Operating income +514.5% · Profit +937.7% — against Q3 FY2024
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingReported another event
Read the filingCompleted an acquisition or disposal · Made a Regulation FD disclosure
Read the filingReported another event
Read the filingThe first 40 of 112. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-27. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Mexico Prefabricated Crown and Bridge Materials Market Outlook to 2036: Permanent Crowns and Bridges Revenue, Volume and Pricing
Yahoo ·
Elevance Health (ELV) Surpasses Q3 Earnings and Revenue Estimates
Yahoo ·
Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*
Yahoo ·
Solventum Receives FDA Clearance For Combined Use Of Restrata Synthetic Electrospun Fiber Matrix, Solventum V.A.C. Therapy
Benzinga ·
Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026
Yahoo ·
How To Retire: Hope For 95, Prepare For 105
SeekingAlpha ·
Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive?
Yahoo ·
Stock Picks From Seeking Alpha's September 2026 New Analysts
SeekingAlpha ·
3 Overrated Stocks We Approach with Caution
Yahoo ·
2 Profitable Stocks for Long-Term Investors and 1 We Question
Yahoo ·
How Is Solventum's Stock Performance Compared to Other Healthcare Stocks
Yahoo ·
Ostomy Dressing Market Forecasts Growth from $3.80B (2026) to $4.73B by 2031, Profiling Coloplast, ConvaTec, Hollister, B. Braun & Salts Healthcare
Yahoo ·
Primary sources and further research